$PET
Wag! Group Co. Stock $pet

$pet Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000184235623000014 Filed on May 12, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$19.82M	$20.62M	$0.00
YoY Change
Cost Of Revenue	$3.303M	$1.026M	$820.0K
YoY Change	63.19%	25.12%
Gross Profit	$16.52M	$19.60M	$8.850M
YoY Change	-19.14%	121.44%
Gross Profit Margin	83.34%	95.02%
Selling, General & Admin	$15.58M	$18.26M	$2.182M
YoY Change	892.61%	736.74%
% of Gross Profit	94.32%	93.17%	24.66%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$375.0K	$381.0K	$152.0K
YoY Change	26.26%	150.66%
% of Gross Profit	2.27%	1.94%	1.72%
Operating Expenses	$15.58M	$18.26M	$2.182M
YoY Change	892.61%	736.74%
Operating Profit	$938.0K	$1.338M	-$2.182M
YoY Change	-159.76%	-161.32%	18656.65%
Interest Expense	$1.659M	-$1.630M	$10.20K
YoY Change	834.44%	-16080.39%
% of Operating Profit	176.87%	-121.82%
Other Income/Expense, Net	-$65.00K	$56.00K	$10.20K
YoY Change	-136.61%	448.91%
Pretax Income	-$4.384M	-$3.787M	-$2.172M
YoY Change	214.95%	74.36%
Income Tax	$38.00K	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$3.869M	-$3.787M	-$2.172M
YoY Change	177.95%	74.36%	18568.96%
Net Earnings / Revenue	-19.52%	-18.36%
Basic Earnings Per Share	-$0.10	-$0.10	-$0.38
Diluted Earnings Per Share	-$0.10	-$0.10	-$138.5K
COMMON SHARES
Basic Shares Outstanding	37.49M shares	37.43M shares	15.69M
Diluted Shares Outstanding	38.11M shares	37.07M shares	6.121M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$24.80M	$24.50M	$335.2K
YoY Change	14639.97%	7210.54%
Cash & Equivalents	$24.79M	$24.50M	$335.2K
Short-Term Investments
Other Short-Term Assets	$2.000M	$2.021M	$332.1K
YoY Change	530.42%	508.5%
Inventory
Prepaid Expenses
Receivables	$7.762M	$8.223M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$34.54M	$34.75M	$735.9K
YoY Change	6133.28%	4621.71%
LONG-TERM ASSETS
Property, Plant & Equipment	$89.00K	$89.00K
YoY Change
Goodwill	$5.096M	$4.501M
YoY Change
Intangibles	$7.814M	$8.173M
YoY Change
Long-Term Investments			$125.0M
YoY Change
Other Assets	$2.092M	$1.529M	$119.7K
YoY Change	4253.8%	1177.04%
Total Long-Term Assets	$16.30M	$14.90M	$125.1M
YoY Change	-86.98%	-88.09%
TOTAL ASSETS
Total Short-Term Assets	$34.54M	$34.75M	$735.9K
Total Long-Term Assets	$16.30M	$14.90M	$125.1M
Total Assets	$50.84M	$49.65M	$125.9M
YoY Change	-59.59%	-60.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.672M	$6.715M	$52.50K
YoY Change	11765.59%	12691.45%
Accrued Expenses	$4.150M	$4.515M	$2.334M
YoY Change	14.6%	93.42%
Deferred Revenue	$2.627M	$2.554M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.427M	$1.344M
YoY Change
Total Short-Term Liabilities	$18.88M	$16.15M	$2.387M
YoY Change	409.85%	576.47%
LONG-TERM LIABILITIES
Long-Term Debt	$25.57M	$25.27M	$0.00
YoY Change
Other Long-Term Liabilities	$218.0K	$703.0K	$4.375M
YoY Change	-95.02%	-83.93%
Total Long-Term Liabilities	$25.79M	$25.27M	$4.375M
YoY Change	489.44%	477.6%
TOTAL LIABILITIES
Total Short-Term Liabilities	$18.88M	$16.15M	$2.387M
Total Long-Term Liabilities	$25.79M	$25.27M	$4.375M
Total Liabilities	$45.80M	$42.12M	$6.762M
YoY Change	466.92%	522.9%
SHAREHOLDERS EQUITY
Retained Earnings	-$156.1M	-$152.2M	-$5.893M
YoY Change	1988.01%	2482.59%
Common Stock	$4.000K	$4.000K	$318.00
YoY Change	1157.86%	1157.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$5.044M	$7.531M	-$5.893M
YoY Change
Total Liabilities & Shareholders Equity	$50.84M	$49.65M	$125.9M
YoY Change	-59.59%	-60.55%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$3.869M	-$3.787M	-$2.172M
YoY Change	177.95%	74.36%	18568.96%
Depreciation, Depletion And Amortization	$375.0K	$381.0K	$152.0K
YoY Change	26.26%	150.66%
Cash From Operating Activities	$1.253M	-$3.580M	-$352.4K
YoY Change	-850.7%	915.84%	2929.22%
INVESTING ACTIVITIES
Capital Expenditures	$15.00K	$16.00K	$5.000K
YoY Change		220.0%
Acquisitions		$9.000M	$0.00
YoY Change
Other Investing Activities	-$710.0K	-$10.65M	-$6.720M
YoY Change		58.41%
Cash From Investing Activities	-$725.0K	-$10.66M	-$6.720M
YoY Change		58.65%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net		$277.0K	$110.0K
YoY Change		151.82%
Cash From Financing Activities	-238.0K	-$223.0K	0.000
YoY Change			-100.0%
NET CHANGE
Cash From Operating Activities	1.253M	-$3.580M	-352.4K
Cash From Investing Activities	-725.0K	-$10.66M	-$6.720M
Cash From Financing Activities	-238.0K	-$223.0K	0.000
Net Change In Cash	290.0K	-$14.46M	-352.4K
YoY Change	-273.75%	4004.21%	-1844.3%
FREE CASH FLOW
Cash From Operating Activities	$1.253M	-$3.580M	-$352.4K
Capital Expenditures	$15.00K	$16.00K	$5.000K
Free Cash Flow	$1.238M	-$3.596M	-$357.4K
YoY Change		906.1%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001842356
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-40764
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	WAG! GROUP CO.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-2546501
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	55
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Francisco Street,
CY2023Q1	dei	Entity Address Address Line3 EntityAddressAddressLine3	Suite 360
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	San Francisco,
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94133
CY2023Q1	dei	City Area Code CityAreaCode	707
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	324-4219
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	37488892	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24502000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	38966000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8223000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5872000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2021000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2585000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	34746000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	47423000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	89000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	88000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	612000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	695000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	8173000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2590000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	4501000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	1451000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1529000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	64000	usd
CY2023Q1	us-gaap	Assets Assets	49650000	usd
CY2022Q4	us-gaap	Assets Assets	52311000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	6715000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7174000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4515000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4765000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2554000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2232000	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	750000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	750000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	268000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	306000	usd
CY2023Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	1344000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1264000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	16146000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16491000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	385000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	435000	usd
CY2023Q1	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	6400000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	7000000	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	25270000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	24970000	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	318000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	493000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	42119000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	42389000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	110000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	110000000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37429251	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36849076	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	4000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	4000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	159731000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	158335000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-152204000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-148417000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	7531000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	9922000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	49650000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	52311000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	20623000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9666000	usd
CY2023Q1	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	1026000	usd
CY2022Q1	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	806000	usd
CY2023Q1	pet	Platform Operations And Support Expense PlatformOperationsAndSupportExpense	3170000	usd
CY2022Q1	pet	Platform Operations And Support Expense PlatformOperationsAndSupportExpense	2577000	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	13275000	usd
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	6082000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4984000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2367000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	381000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	152000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	22836000	usd
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	11984000	usd
CY2023Q1	us-gaap	Other Income OtherIncome	56000	usd
CY2022Q1	us-gaap	Other Income OtherIncome	0	usd
CY2023Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-1630000	usd
CY2022Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-32000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3787000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2350000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-3787000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2350000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.38
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.38
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37065450	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37065450	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6121253	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6121253	shares
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	9922000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	54000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1342000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-3787000	usd
CY2023Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2023Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	7531000	usd
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	23858824	shares
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	110265000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-106113000	usd
CY2022Q1	pet	Temporary Equity Stock Issued During Period Shares New Issues TemporaryEquityStockIssuedDuringPeriodSharesNewIssues	1100000	shares
CY2022Q1	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	10925000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	54000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2350000	usd
CY2022Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	24958824	shares
CY2022Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	121190000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-108409000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-3787000	usd
CY2022Q1	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	0	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2350000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1342000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	54000	usd
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-657000	usd
CY2022Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	381000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	152000	usd
CY2023Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	28000	usd
CY2022Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	30000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2351000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	861000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-537000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-117000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-459000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1719000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	0	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	47000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-250000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1288000	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	322000	usd
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	135000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3580000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2245000	usd
CY2023Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	0	usd
CY2022Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	10079000	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	0	usd
CY2022Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	3551000	usd
CY2023Q1	us-gaap	Payment For Contingent Consideration Liability Investing Activities PaymentForContingentConsiderationLiabilityInvestingActivities	175000	usd
CY2022Q1	us-gaap	Payment For Contingent Consideration Liability Investing Activities PaymentForContingentConsiderationLiabilityInvestingActivities	187000	usd
CY2023Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	9000000	usd
CY2022Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
CY2023Q1	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	1470000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	16000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10661000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6720000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	54000	usd
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2023Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	277000	usd
CY2022Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	110000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	0	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	10925000	usd
CY2023Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	usd
CY2022Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1151000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-223000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9664000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-14464000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	699000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	38966000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2628000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24502000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3327000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	1203000	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	4000	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2023Q1	pet	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.97
CY2022Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	91130	shares
CY2022Q3	pet	Number Of Lenders NumberOfLenders	2	lender
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities and disclosures as of the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates on various factors, including historical experience, and on various other assumptions that are believed to be reasonable under the circumstances, when these carrying values are not readily available from other sources.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant items subject to estimates and assumptions include, but are not limited to, fair values of financial instruments, assumptions used in the valuation of common and preferred stock, valuation of stock-based compensation and warrants, and the valuation allowance for deferred income taxes. Actual results may differ from these estimates.</span></div>
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-152200000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-148400000	usd
CY2023Q1	us-gaap	Payments To Acquire Interest In Subsidiaries And Affiliates PaymentsToAcquireInterestInSubsidiariesAndAffiliates	1500000	usd
CY2022Q1	us-gaap	Advertising Expense AdvertisingExpense	1900000	usd
CY2022Q1	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2023Q1	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022Q3	pet	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.97
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	Cash, cash equivalents, investments, and amounts at payment processors are potentially subject to concentration of credit risk. Such balances are maintained at financial institutions that management determines to be of high-credit quality. Cash accounts at each institution are insured by the Federal Deposit Insurance Corporation ("FDIC") up to certain limits. At times, such deposits may be in excess of the FDIC insurance limit. The Company has not experienced any losses on its deposits.
CY2023Q1	us-gaap	Advertising Expense AdvertisingExpense	2100000	usd
CY2022Q3	pet	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.97
CY2022Q3	pet	Proceeds From Redemption Of Common Stock ProceedsFromRedemptionOfCommonStock	29100000	usd
CY2022Q3	pet	Proceeds From Redemption Of Common Stock Classified As Restricted Cash Current ProceedsFromRedemptionOfCommonStockClassifiedAsRestrictedCashCurrent	23900000	usd
CY2022Q3	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	5000000	usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	pet	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.97
CY2022Q3	pet	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.97
CY2022Q3	pet	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.97
CY2022Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	24700000	usd
CY2022Q3	pet	Derivative Instrument Contingent Consideration Liability Shares DerivativeInstrumentContingentConsiderationLiabilityShares	2393378	shares
CY2022Q3	pet	Derivative Instrument Contingent Consideration Liability Price Per Share DerivativeInstrumentContingentConsiderationLiabilityPricePerShare	10.30
CY2022Q4	pet	Derivative Instrument Contingent Consideration Liability Shares DerivativeInstrumentContingentConsiderationLiabilityShares	955000	shares
CY2022Q4	pet	Derivative Instrument Contingent Consideration Liability Repurchase Price DerivativeInstrumentContingentConsiderationLiabilityRepurchasePrice	14800000	usd
CY2022Q4	pet	Derivative Instrument Contingent Consideration Liability Shares DerivativeInstrumentContingentConsiderationLiabilityShares	955000	shares
CY2022Q4	pet	Derivative Instrument Contingent Consideration Liability Proceeds From Release Of Restricted Cash DerivativeInstrumentContingentConsiderationLiabilityProceedsFromReleaseOfRestrictedCash	9800000	usd
CY2022Q3	pet	Cash Acquired Through Reverse Recapitalization CashAcquiredThroughReverseRecapitalization	28330000	usd
CY2022Q3	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	5202000	usd
CY2022Q3	pet	Payments Of Reverse Recapitalization Transaction Costs PaymentsOfReverseRecapitalizationTransactionCosts	12488000	usd
CY2022Q3	pet	Reverse Recapitalization Accrued Transaction Costs ReverseRecapitalizationAccruedTransactionCosts	9318000	usd
CY2022Q3	pet	Reverse Recapitalization Net ReverseRecapitalizationNet	11726000	usd
CY2022Q3	pet	Reverse Recapitalization Reversal Of Additional Paid In Capital Impact Recorded Upon Issuance Of Forward Purchase Agreements ReverseRecapitalizationReversalOfAdditionalPaidInCapitalImpactRecordedUponIssuanceOfForwardPurchaseAgreements	23203000	usd
CY2022Q4	pet	Derivative Instrument Contingent Consideration Liability Proceeds From Release Of Restricted Cash DerivativeInstrumentContingentConsiderationLiabilityProceedsFromReleaseOfRestrictedCash	9837000	usd
CY2022Q4	pet	Reverse Recapitalization Additional Paid In Capital Impact Of Forward Purchase Agreement Net Of Cash Received ReverseRecapitalizationAdditionalPaidInCapitalImpactOfForwardPurchaseAgreementNetOfCashReceived	4229000	usd
CY2022Q4	pet	Reverse Recapitalization Net ReverseRecapitalizationNet	2589000	usd
CY2022Q3	pet	Stock Issued During Period Shares Reverse Recapitalization StockIssuedDuringPeriodSharesReverseRecapitalization	6523530	shares
CY2022Q3	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	122434	shares
CY2022Q3	pet	Stock Issued During Period Shares Reverse Recapitalization And Other StockIssuedDuringPeriodSharesReverseRecapitalizationAndOther	6645964	shares
CY2022Q3	pet	Stock Converted Reverse Recapitalization StockConvertedReverseRecapitalization	31100000	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37745964	shares
CY2022Q3	pet	Derivative Instrument Contingent Consideration Liability Shares DerivativeInstrumentContingentConsiderationLiabilityShares	2393378	shares
CY2022Q3	us-gaap	Shares Outstanding SharesOutstanding	30863283	shares
CY2022Q4	pet	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.97
CY2022Q3	pet	Reverse Recapitalization Contingent Consideration Equity Earnout Period ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriod	P3Y
CY2022Q3	pet	Stock Issued During Period Value Reverse Recapitalization Contingent Consideration Equity StockIssuedDuringPeriodValueReverseRecapitalizationContingentConsiderationEquity	23900000	usd
CY2023Q1	pet	Reverse Recapitalization Transaction Costs ReverseRecapitalizationTransactionCosts	39500000	usd
CY2023Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2600000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2200000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	20623000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9666000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	400000	usd
CY2022Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	100000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P30M
CY2022Q4	pet	Lessee Future Operating Lease Monthly Base Rent LesseeFutureOperatingLeaseMonthlyBaseRent	20400	usd
CY2022Q4	pet	Lessee Future Operating Lease Monthly Rent Increase Percent LesseeFutureOperatingLeaseMonthlyRentIncreasePercent	0.030
CY2022Q4	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P13M
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	100000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	187000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	248000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	255000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	43000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	733000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y2M12D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.084
CY2019Q4	us-gaap	Income Tax Examination Estimate Of Possible Loss IncomeTaxExaminationEstimateOfPossibleLoss	1200000	usd
CY2022Q2	us-gaap	Income Tax Examination Liability Refund Adjustment From Settlement With Taxing Authority IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority	-1200000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	988000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	1751000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	30227000	usd
CY2023Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	32966000	usd
CY2022Q3	pet	Line Of Credit Facility Financial Covenants Minimum Liquidity LineOfCreditFacilityFinancialCovenantsMinimumLiquidity	5000000	usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	110000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	110000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37429251	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37429251	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36849076	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36849076	shares
CY2023Q1	pet	Common Stock Exchange Ratio CommonStockExchangeRatio	0.97
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1342000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	54000	usd
CY2023Q1	pet	Number Of Lenders NumberOfLenders	2
CY2021Q3	pet	Fair Value Of Warrants Price FairValueOfWarrantsPrice	1.32
CY2023Q1	pet	Class Of Warrant Or Right Redemption Of Warrants Or Rights Reference Price ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsReferencePrice	16.50
CY2023Q1	pet	Class Of Warrant Or Right Redemption Of Warrants Or Rights Threshold Trading Days ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays	20	day
CY2023Q1	pet	Class Of Warrant Or Right Redemption Of Warrants Or Rights Consecutive Trading Days ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsConsecutiveTradingDays	30	day
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.38
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-3787000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2350000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37065450	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37065450	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6121253	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6121253	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.38
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	44152692	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	36148475	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0

Files In Submission

Name	View Source	Status
pet-20230331_pre.xml	Edgar Link	unprocessable
pet-20230331_def.xml	Edgar Link	unprocessable
0001842356-23-000014-index-headers.html	Edgar Link	pending
0001842356-23-000014-index.html	Edgar Link	pending
0001842356-23-000014.txt	Edgar Link	pending
0001842356-23-000014-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pet-20230331.htm	Edgar Link	pending
pet-20230331.xsd	Edgar Link	pending
pet-20230331xex311.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
pet-20230331xex312.htm	Edgar Link	pending
pet-20230331xex321.htm	Edgar Link	pending
pet-20230331_g1.jpg	Edgar Link	pending
pet-20230331_g2.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
pet-20230331_cal.xml	Edgar Link	unprocessable
pet-20230331_lab.xml	Edgar Link	unprocessable
pet-20230331_htm.xml	Edgar Link	completed
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PET
Wag! Group Co. Stock $pet

2023 Q2 Form 10-Q Financial Statement

#000184235623000014 Filed on May 12, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PET Wag! Group Co. Stock $pet

2023 Q2 Form 10-Q Financial Statement

#000184235623000014 Filed on May 12, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PET
Wag! Group Co. Stock $pet